Literature DB >> 25185188

A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow.

Don L Gibbons1, Lauren Averett Byers2.   

Abstract

SUMMARY: Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25185188      PMCID： PMC4990388          DOI： 10.1158/2159-8290.CD-14-0791

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  Paths of resistance to EGFR inhibitors: is NF enough?

Authors:  Ophélia Maertens; Karen Cichowski
Journal:  Cancer Discov       Date:  2014-05       Impact factor: 39.397

2.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

3.  Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Camelia S Sima; Gregory J Riely; Juliann Chmielecki; Mark G Kris; William Pao; Marc Ladanyi; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

4.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

5.  Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Authors:  Yelena Y Janjigian; Christopher G Azzoli; Lee M Krug; Leanne K Pereira; Naiyer A Rizvi; M Catherine Pietanza; Mark G Kris; Michelle S Ginsberg; William Pao; Vincent A Miller; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2011-01-19       Impact factor: 12.531

6.  An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Authors:  Lauren Averett Byers; Lixia Diao; Jing Wang; Pierre Saintigny; Luc Girard; Michael Peyton; Li Shen; Youhong Fan; Uma Giri; Praveen K Tumula; Monique B Nilsson; Jayanthi Gudikote; Hai Tran; Robert J G Cardnell; David J Bearss; Steven L Warner; Jason M Foulks; Steven B Kanner; Varsha Gandhi; Nancy Krett; Steven T Rosen; Edward S Kim; Roy S Herbst; George R Blumenschein; J Jack Lee; Scott M Lippman; K Kian Ang; Gordon B Mills; Waun K Hong; John N Weinstein; Ignacio I Wistuba; Kevin R Coombes; John D Minna; John V Heymach
Journal:  Clin Cancer Res       Date:  2012-10-22       Impact factor: 12.531

7.  Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Authors:  Valentina Pirazzoli; Caroline Nebhan; Xiaoling Song; Anna Wurtz; Zenta Walther; Guoping Cai; Zhongming Zhao; Peilin Jia; Elisa de Stanchina; Erik M Shapiro; Molly Gale; Ruonan Yin; Leora Horn; David P Carbone; Philip J Stephens; Vincent Miller; Scott Gettinger; William Pao; Katerina Politi
Journal:  Cell Rep       Date:  2014-05-09       Impact factor: 9.423

8.  Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

Authors:  Shigeru Kawabata; José R Mercado-Matos; M Christine Hollander; Danielle Donahue; Willie Wilson; Lucia Regales; Mohit Butaney; William Pao; Kwok-Kin Wong; Pasi A Jänne; Phillip A Dennis
Journal:  Cell Rep       Date:  2014-06-12       Impact factor: 9.423

9.  Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

Authors:  Lucia Regales; Yixuan Gong; Ronglai Shen; Elisa de Stanchina; Igor Vivanco; Aviva Goel; Jason A Koutcher; Maria Spassova; Ouathek Ouerfelli; Ingo K Mellinghoff; Maureen F Zakowski; Katerina A Politi; William Pao
Journal:  J Clin Invest       Date:  2009-09-14       Impact factor: 14.808

10.  Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

Authors:  Yelena Y Janjigian; Egbert F Smit; Harry J M Groen; Leora Horn; Scott Gettinger; D Ross Camidge; Gregory J Riely; Bushi Wang; Yali Fu; Vikram K Chand; Vincent A Miller; William Pao
Journal:  Cancer Discov       Date:  2014-07-29       Impact factor: 39.397
  10 in total
  5 in total

1.  Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy.

Authors:  Lai Yue Chan; David J Craik; Norelle L Daly
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

Review 2.  Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer.

Authors:  Elizabeth S Waxman; Frank V Fossella
Journal:  J Adv Pract Oncol       Date:  2016-07-01

Review 3.  The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.

Authors:  Hasan Baysal; Ines De Pauw; Hannah Zaryouh; Marc Peeters; Jan Baptist Vermorken; Filip Lardon; Jorrit De Waele; An Wouters
Journal:  Front Immunol       Date:  2021-09-07       Impact factor: 7.561

Review 4.  Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer.

Authors:  Hyung Kwon Byeon; Jaemoon Yang; Minhee Ku
Journal:  Exp Mol Med       Date:  2019-01-16       Impact factor: 8.718

5.  DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model.

Authors:  Takeshi Jimbo; Mana Hatanaka; Takahiro Komatsu; Tomoe Taira; Kentaro Kumazawa; Naoyuki Maeda; Takashi Suzuki; Masahiro Ota; Noriyasu Haginoya; Takeshi Isoyama; Kosaku Fujiwara
Journal:  Oncotarget       Date:  2019-08-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.